tbuckley/cabot-search huggingface dataset:
AB1238-HPR People's perceptions of their phone call with rheuma directly, a rheumatic diseases helpline
Authors: S Arvidsson, M Nylander, S Bergman
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Information on rheumatic diseases is often complex to understand or scary, and additional support is often necessary. Rheuma Directly (RD) is a helpline with specially trained nurses on rheumatic diseases, funded by the Swedish Rheumatism Association and Spenshult Research and Development Centre. Little is known of how people calling a helpline perceive the contact. <h3>Objectives</h3> To describe the variation in how people perceive the contact with the helpline RD. <h3>Methods</h3> The study had a descriptive, qualitative design with a phenomenographic approach and was carried out by means of 27 semi-structured telephone interviews. The informants were 22 female and 5 men, and their ages ranged from 22 to 89 years (mean 54 years). <h3>Results</h3> The informants called RD when they had problems getting answers to their questions through the Internet or from healthcare professionals. Three different description categories emerged: Specific competence, Constructive dialogue, and Applicability. The informants9 perceived Specific competence when the nurses were knowledgeable, the call was complementary to previously received information and when the informants had greater knowledge after the contact with RD. They perceived that it was a Constructive dialogue when they got someone to discuss with, a "sounding board", and perceived emotional support, felt reassured and were satisfied with the answer. The informants perceived Applicability because RD was available and they could make different choices according to their own desire; before (how and when they would contact RD), during (what to tell and what question they would ask) and after (how and what they would do after the contact with RD). <h3>Conclusions</h3> People calling RD perceived that the telephone call with the nurses meant meeting specific competence, gaining constructive dialogue and that the helpline was applicable. This knowledge ad to a fuller understanding of factors that from a caller9s perspective, are important when calling a helpline with specially trained nurses on rheumatic diseases. <h3>Disclosure of Interest</h3> None declared
AB0791 High prevalence of metabolic disorders and obesity in psoriatic arthritis compared to psoriasis alone: a retrospective dermatological clinic-based study
Authors: N Batkaeva, T Korotaeva, E Batkaev
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> An association between increased adiposity, obesity (Obs), and psoriasis has emerged. In addition to obesity, patients with psoriasis are more likely to have metabolic syndrome. <h3>Objectives</h3> to evaluate the prevalence of endocrine diseases, nutritional and metabolic disorder (ENMD) comorbidity in patients (pts) with PsA and Psoriasis (PsO) patients without arthritis in the dermatological hospital cohort. <h3>Methods</h3> 889 pts (Male-516/Female-329) with moderate-to-severy plaque PsO, mean age 50.4±17.6 years, mean PsO duration 21.5±14.7 were included. PsO pts with Endocrine, nutritional and metabolic diseases (E00-E90) (ENMD), including Disorders of thyroid gland (E00–E07), Obesity and other hyperalimentation (E65-E68), Diabetes mellitus (E10-E14) (DM) were identify in the hospital Database reporting and coding by International Statistical Classification of Disease and Related Health Problems (ICD-10) between 2010 - 2015 years. M±m, t-test, χ<sup>2</sup>, (%) were calculated. All p&lt;0.05 were considered to indicate statistical significance. <h3>Results</h3> 302 out of 889 pts (33.9%) had PsA and 587 out of 889 pts (66.1%) had PsO alone. PsA pts were older then PsO pts – 55.3±13.7 and 50.4±17.6 (p&lt;0.001). 155 out of 889 pts (17.4%) had ENMD. In PsA pts ENMD were found in significantly more cases than in PsO pts – in 76 out of 302 pts (25.2%) and in 79 out of 587 pts (13.5%) accordingly (χ<sup>2</sup>=18.986, df=2, p&lt;0.00001). In PsA pts ENMD coding as E00–E07 were found in significantly more cases than in PsO pts – in 25 out of 302 pts (8.3%) and in 23 out of 587 pts (3.9%) accordingly (χ<sup>2</sup>=7.4211, df=2, p=0.00645). Obs coding as E65-E68 were found in significantly more cases in PsA pts compare to PsO pts - in 54 out of 302 pts (17.9%) and in 64 out of 587 pts (10.9%) accordingly (χ<sup>2</sup>=8.4345, df=2, p=0.00368). DM coding as E10-E14 were found in more cases in PsA pts compare to PsO pts - in 54 out of 302 pts (17.9%) and in 83 out of 587 pts (14.1%) accordingly (χ<sup>2</sup>=2.1410, df=2, p=0.14341). <h3>Conclusions</h3> ENMD comorbidities are common for PsA and PsO without arthritis pts. Obs and disorders of thyroid gland were found in significantly more cases in PsA pts compare to PsO pts. Obesity and PsA are an unhealthy combination. Obesity may represent an additive cardio-metabolic risk factor in PsA subjects. High frequency of ENMD in PsA than PsO could be due to share inflammation pathways with insulin resistance and age. Patients with more severe psoriasis are at higher odds of endocrine, nutritional and metabolic diseases compared with those with mild psoriasis. <h3>Disclosure of Interest</h3> None declared
AB0982 Analysis of the treatment efficacy for retroperitoneal fibrosis - a case series. suspicion of erdheim-chester disease in a patient with an initial diagnosis of retroperitoneal fibrosis, refractory to standard treatment
Authors: J Koblowski, A Juszkiewicz, M Kania-Pudło, W Tlustochowicz
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Retroperitoneal fibrosis (RPF) is a rare disorder characterized by the development of fibrotic tissue in the retroperitoneum involving the abdominal aorta, iliac arteries and ureters. Erdheim-Chester disease (ECD) is a rare, non-Langerhans histiocytosis. Symptoms of ECD often resemble retroperitoneal fibrosis. <h3>Objectives</h3> Evaluation of standard treatment efficacy in 13 consecutive RPF patients. Revision of the diagnosis in patients unresponsive to standard therapy. <h3>Methods</h3> A retrospective analysis of 13 consecutive RPF patients (10 males and 3 females) treated in our department since 2008 was performed. All patients were treated with tapered dose of steroids combined with an immunosuppressive agent (cyclophosphamide in 4, azathioprine in 9, methotrexate in 6, hydroxychloroquine in 5 patients). Urologic interventions were undertaken as necessary. <h3>Results</h3> The treatment was effective in 10 patients: reduction of the retroperitoneal mass in computed tomography (CT) and normalization of the laboratory tests, including markers of inflammation and creatinine concentration. No improvement was found in 3 patients. However, in a further diagnostic work-up the diagnosis of RPF was maintained only in one of these 3 patients. In the second pateint an ANCA-asssotiated vasculitus was ultimately diagnosed. The third patient was treated with a combination of steroids and cyclophosphamide without any radiological improvement. However, the revision of CTs revealed the presence of changes typical of Erdheim-Chester disease. <h3>Conclusions</h3> The standard treatment (based on a combination of steroids and immunosuppressive drugs) is efficient in most partients with RPF. In refractory cases an alternative diagnosis, such as systemic vasculitis or Erdheim-Chester disease, should be taken into account. <h3>References</h3> Diamond El et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood. 2014 Jul 24;124(4):483–92. Kermani TA et al. Idiopathic retroperitoneal fibrosis: a retrospective review of clinical presentation, treatment, and outcomes. Mayo Clin Proc. 2011 Apr;86(4):297–303. <h3>Disclosure of Interest</h3> None declared
OP0041 All-cause, cardiovascular and malignancy related mortality in systemic lupus erythematosus (SLE): a population-based study
Authors: B Moghaddam, JA Avina-Zubieta, EC Sayre
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> SLE is associated with increased risk of overall mortality; however morality trends due to specific causes including cardiovascular disease (CVD), malignancies or other causes are largely unknown. <h3>Objectives</h3> Our objective was to assess trends in cause-specific mortality among SLE patients between January 1, 1997 and December 31, 2012 in a general population-based context. <h3>Methods</h3> We conducted a population-based matched cohort on SLE patients diagnosed between January 1,1997 and December 31,2012 using an administrative health database from the province of British Columbia, Canada. We identified all incident cases of SLE and up to 10 non-SLE controls matched on sex, age, and calendar year of study entry. The cohort was divided into two cohorts based on year of SLE diagnosis (1997–2004 and 2005–2012). All-cause mortality and cause-specific incidence of death rates (IR) were calculated. Cox proportional hazard regression models were used to estimate the mortality hazard ratios (HR), adjusting for possible confounders (i.e. Charlson Comorbidity Index, number of outpatient visits, hospitalization, cardiovascular medications, glucocorticoids and NSAIDs at baseline). <h3>Results</h3> 4238 SLE and 42380 matched controls were studied. SLE patients had significantly increased all-cause mortality with HR 1.29 (95% CI, 1.15–1.46) and increased cause-specific mortality from CVD and other causes with HRs of 1.43 (95% CI, 1.15 -1.79) and 1.74 (95% CI, 1.46–2.09), respectively. The cohorts did not differ in the rate of death from malignancy. SLE patients had an approximately 2-fold increase in death from other causes in both early (HR 1.86 (95% CI 1.33–2.60)) and recent cohorts (HR 1.90 (95% CI 1.42–2.56)). There was no significant improvement in all-cause and cause-specific mortality trends between the two cohorts. <h3>Conclusions</h3> This study demonstrates that despite advances in therapy with novel biologic agents, there are no significant differences in all-cause and CVD mortality from SLE between early and recent cohorts. Death from other causes, which includes a composite of death related to for example renal disease and infections, remains high suggesting areas for future targeted research and therapy. <h3>Disclosure of Interest</h3> None declared
THU0373 Use of corticosteroid hip joint injections in spondyloarthritis patients under tnf alpha inhibitors
Authors: K Maatallah, A Ben Ouhiba, I Mahmoud, S Belghali, W Hamdi, M Kchir, R Tekaya, L Abdelmoula
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> The hip disease is a serious complication of spondyloarthritis (SpA), engaging the functional prognosis of patients. TNF alpha inhibitors are a breakthrough for the treatment of SpA and the management of this complication. <h3>Objectives</h3> To assess the efficacy of TNF alpha inhibitors on hip involvement in SpA by evaluating the use of intra-articular corticosteroid infiltrations. <h3>Methods</h3> Observational cohort study that included 94 SpA patients with hip disease (ASAS2009). Two groups were studied. Group 1 (G1): patients under anti-TNF alpha therapy and Group 2 (G2): TNF alpha inhibitors naive patients. Clinical (BASDAI, BASFI, hip (pain/mobility), index of severity for osteoarthritis for the hip (ISH)), biological (CRP) data were assessed and the use of corticosteroid hip joint infiltration was compared. Evaluations were performed and compared between the 2 groups at baseline (T0), two years (T2) and Tn (greater than or equal to 3 years). The correlation study was made by Pearson test. A correlation was considered statistically significant if p&lt;0.05. <h3>Results</h3> Group 1 and 2 included 48 and 46 patients respectively. The socio demographic and clinical characteristics of the disease were comparable between the two groups. Biological and radiological assessments of the two groups were comparable at T0. Group 1 had however a more active disease and a greater functional impairment. NSAIDs were prescribed in 40% of patients in G1 and 86% in G2 (p&lt;0.0001). DMARDS were prescribed in 20 patients in G1 and in 22 patients in G2 (p=0.6). In G1 patients received infliximab, adalimumab and etanercept in 48%, 15% and 37% of cases respectively. Four patients of G1 and three of G2 patients received intra-articular corticosteroid infiltration in the year prior to the initial assessment (p=0.7). Assessment at T2 showed a greater improvement in clinical and biological parameters of the disease in group 1 than in group 2 with Δ (T2-T0) significantly lower in group 1 for the BASDAI (p&lt;0.0001), the BASFI (p&lt;0.0001) and the ISH (p=0.017). The number of painful hip was significantly lower in group 1 (p&lt;0.0001). The evaluation at Tn showed a sustained clinical and biological efficacy of TNF alpha inhibitors in Group 1. The use of corticosteroid injections was significantly higher in group 2. Table 1 summarizes the assessment of different parameters at T2 and Tn. <h3>Conclusions</h3> Hip involvement is a marker of severity of spondyloarthritis. Anti-TNF alpha treatment is effective on hip disease. It reduces the use of intra articular injections of corticosteroids. <h3>Disclosure of Interest</h3> None declared
SP0167 Horizon 2020: opportunities for medical research and innovation
Authors: S Hogan
Journal: Annals of the Rheumatic Diseases (2017)

Horizon 2020 is the largest EU Research and Innovation programme ever with nearly €80 billion of funding available over 7 years (2014 to 2020). It is an opportunity for supporting excellence and collaboration in research, on a scale and scope that is seldom feasible at global level. Horizon 2020 contributes to the Innovation Union, a Europe 2020 flagship initiative aimed at securing Europe9s global competitiveness. By coupling research and innovation, Horizon 2020 is helping to achieve this with its emphasis on excellent science, industrial leadership and tackling societal challenges. The goal is to ensure Europe produces world-class science, removes barriers to innovation and makes it easier for the public and private sectors to work together in delivering innovation. This it is seen as a means to drive economic growth and create jobs, Horizon 2020 has the political backing of Europe9s leaders and the Members of the European Parliament. Horizon 2020 is open to everyone, with simplified and more rapid application and reporting procedures. The next work programme for the period 2018 – 2020 will be published in Autumn 2017. <h3>Disclosure of Interest</h3> None declared
Lightweight Exosuit Could Help Patients Walk After Stroke
Authors: Jennifer Abbasi
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THU0113 Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal c-reactive protein
Authors: J Hurnakova, H Hulejova, J Zavada, M Komarc, L Andres Cerezo, H Mann, J Vencovsky, K Pavelka, L Senolt
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> About a half of patients with rheumatoid arthritis (RA) have normal or low C-reactive protein (CRP) levels<sup>1–3</sup>. Calprotectin is a promising and probably more specific biomarker of disease activity than conventionally used acute phase reactants. <h3>Objectives</h3> The aim of this study was to analyse levels of serum calprotectin in RA patients with clinically active disease and with low CRP (&lt;10 mg/L). <h3>Methods</h3> A total of 160 RA patients and 32 healthy subjects were enrolled in this study. All patients underwent clinical examination (DAS28). The levels of calprotectin were analyzed in patients with moderate to high disease activity with low CRP levels and in healthy subjects. The discriminatory capacity of calprotectin to identify clinically active patients in spite of normal CRP was assessed using ROC curves. <h3>Results</h3> Out of all RA patients, 74/160 (46.3%) had low CRP and were in remission or had low activity at the same time. However, 51/160 (32%) had low CRP levels despite moderate to high disease activity according to DAS28. In these patients, calprotectin levels were significantly higher than in patients with low CRP in remission or with low disease activity at the same time (mean 2.7±1.5 vs. 2.1±1.2 μg/mL, p=0.043) and differed from that in healthy subjects (mean 2.7±1.5 vs. ± 1.9±1.2 μg/mL, p=0.011) (Figure 1). The discriminatory capacity for calprotectin to distinguish clinically active vs. inactive patients in spite of low CRP using AUC of the DAS28 was 0.607 (95% CI 0.503 to 0.711, p=0.043) with an optimal cut-off 2.5 μg/mL. <h3>Conclusions</h3> The present study demonstrates that calprotectin may reflect inflammatory activity in RA patients where CRP fails to do so. <h3>References</h3> Pincus T, Sokka T. Laboratory tests to assess patients with rheumatoid arthritis: advantages and limitations. Rheum Dis Clin North Am 2009;35(4):731–4. Sokka T, Pincus T. Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%&gt;45% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United States. J Rheumatol 2009;36(7):1387–90. Pincus T, Gibson KA, Shmerling RH. An evidence-based approach to laboratory tests in usual care of patients with rheumatoid arthritis. Clin Exp Rheumatol 2014;32(5 Suppl 85):S-23–8. <h3>Acknowledgements</h3> This work was supported by a project of the Ministry of Health of the Czech Republic for conceptual research development by organization [023728], Charles University Grant Agency (GAUK grant), Czech Republic [880217] and Specific Academy Research Projects (SVV) [260 031]. <h3>Disclosure of Interest</h3> None declared
SAT0547 The influence of osteoarthritis on clinical, laboratory and ultrasound parameters of patients with early rheumatoid arthritis
Authors: T Serban, I Satulu, O Vutcanu, M Milicescu, CM Mihai, M Bojinca
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Osteoarthritis (OA) and rheumatoid arthritis (RA) are not infrequent in the general population. The two pathologic entities can overlap and the presence of OA can interfere with the evaluation of patients with RA. <h3>Objectives</h3> This study aims to evaluate the possible impact of OA on the clinical, laboratory and ultrasound parameters currently evaluated in patients with early RA (ERA). <h3>Methods</h3> We have evaluated the data obtained from patients with ERA referred to our Early Arthritis Research Center (EARC). Only data from patients who fulfilled EULAR/ACR 2010 criteria for RA (1) and had a symptom duration of less than 12 months were analyzed. 43 patients were diagnosed with ERA in the EARC between 2012 and 2016 and were enrolled in this study. Patients were evaluated at baseline and after 12 months. All patients underwent clinical examination, laboratory tests and ultrasound (US) examination. For the US examination we have calculated the score proposed by Naredo et al. considering that this simplified US score includes the evaluation of the hand and knee. (2) <h3>Results</h3> There was a clear predominance of women (62.8%). The mean age was 55.47±13.71 years. At baseline, 21 patients (48.8%) were diagnosed with OA. 15 patients (34.9%) presented hand OA and 9 patients (20.9%) presented knee OA. Hand OA didn9t influence the values of DAS28, SDAI, patient9s and physician9s visual analogue scale (VAS) or ultrasound scores (p&gt;0.05). For patients with knee OA, significantly higher values for DAS28 were observed at baseline (p=0.018) and were maintained significantly higher after 12 months of observation (p=0.031). All the other parameters were not influenced by the presence of knee OA (p&gt;0.05). The median value and interquartile range for lab tests and for disease activity indices are shown in Table 1. <h3>Conclusions</h3> Significantly higher values of DAS28 were observed in patients with ERA who associated knee OA, while the values of SDAI were not influenced, suggesting that SDAI may be superior to DAS28 in evaluating patients with ERA and knee OA. Not the same tendency was observed in patients with ERA and hand OA. The values of patient9s VAS were not influenced by the presence of hand or knee OA suggesting that these types of OA do not influence the patients9 perception of the disease activity. Moreover, the values of ultrasound scores were not influenced by the presence of OA. <h3>References</h3> Aletaha D et al. Arhritis Rheum. 2010;62:2569–2581. Naredo E et al. Clin Exp Rheumatol. 2005;23:881–884. <h3>Disclosure of Interest</h3> None declared
PIK3CB/p110β is a selective survival factor for glioblastoma
Authors: Kevin J Pridham, Lamvy Le, Sujuan Guo, Robin T Varghese, Sarah Algino, Yanping Liang, Renee Fajardin, Cara M Rodgers, Gary R Simonds, Deborah F Kelly, Zhi Sheng
Journal: Neuro-Oncology (2017)

Glioblastoma (GBM) is difficult to treat. Phosphoinositide 3-kinase (PI3K) is an attractive therapeutic target for GBM; however, targeting this pathway to effectively treat GBM is not successful because the roles of PI3K isoforms remain to be defined. The aim of this study is to determine whether PIK3CB/p110β, but not other PI3K isoforms, is a biomarker for GBM recurrence and important for cell survival.Gene expression and clinical relevance of PI3K genes in GBM patients were analyzed using online databases. Expression/activity of PI3K isoforms was determined using immunoblotting. PI3K genes were inhibited using short hairpin RNAs or isoform-selective inhibitors. Cell viability/growth was assessed by the MTS assay and trypan blue exclusion assay. Apoptosis was monitored using the caspase activity assay. Mouse GBM xenograft models were used to gauge drug efficacy.PIK3CB/p110β was the only PI3K catalytic isoform that significantly correlated with high incidence rate, risk, and poor survival of recurrent GBM. PIK3CA/p110α, PIK3CB/p110β, and PIK3CD/p110δ were differentially expressed in GBM cell lines and primary tumor cells derived from patient specimens, whereas PIK3CG/p110γ was barely detected. PIK3CB/p110β protein levels presented a stronger association with the activities of PI3K signaling than other PI3K isoforms. Blocking p110β deactivated PI3K signaling, whereas inhibition of other PI3K isoforms had no effect. Specific inhibitors of PIK3CB/p110β, but not other PI3K isoforms, remarkably suppressed viability and growth of GBM cells and xenograft tumors in mice, with minimal cytotoxic effects on astrocytes.PIK3CB/p110β is a biomarker for GBM recurrence and selectively important for GBM cell survival.
Sixty seconds on . . . the Mohawk tribe
Authors: Anne Gulland
Journal: BMJ (2017)

No, absolutely not. It’s a contemporary tale of a drug manufacturer trying to ensure that its drug stays on patent.

The Irish drug firm Allergan is transferring the patents for its dry eye treatment Restasis (cyclosporine ophthalmic emulsion) to the Saint Regis Mohawk Tribe. The tribe has sovereign status under US law, so the drug firm hopes that this …